(MedPage Today) — Uptake of lecanemab (Leqembi), a monoclonal antibody approved to treat early Alzheimer’s disease, appeared to be marked by racial, ethnic, and socioeconomic disparities, an analysis of Medicare data suggested.
Of all Medicare…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/115605
Author :
Publish date : 2025-05-15 20:33:00
Copyright for syndicated content belongs to the linked Source.
